incidence was 0.82 (95% CI: 0.75, 0.89) cases /1,000 population in 2005, increased with age, and was higher in females than in males. SSRI's were the most frequently used ADs. Augmentation with antipsychotics was common. The median time from PTD onset (first AD medication) to TRD onset was 416 days but psychiatrists practicing in Taiwan indicated they would switch within <= 3 months if an AD medication was not effective. We therefore repeated the analysis with a 6 months cap on time from onset of PTD to TRD. In this supplemental, post-hoc, analysis, 68 PTD subjects, 2.47%, (95% CI: 1.94, 3.10) developed TRD; i.e., 0.10 (95% CI: 0.08, 0.12) incident cases/1,000 population.
Introduction
Major depressive disorder (MDD) is a chronic disabling condition associated with high morbidity and mortality. The 12-month prevalence of MDD was estimated as 8% in the US, 3% to 6% in various European countries, and 2% in Japan (Bromet, 2011) and depression is associated with multiple adverse outcomes including marital disruption, unstable employment, and early mortality (Kessler and Bromet, 2013) . The personal and societal costs of a treatment resistant depression (TRD) case are typically higher than those of a treatment-responsive depression case (Mrazek, 2014; Olchanski, 2013) . Recent estimates for the proportion of pharmaceutically treated depression (PTD) that develops into TRD range from 35% in a study limited to PTD subjects with MDD (Nemeroff, 2007) to 6.6% in a study that included a wider range of depressive diagnoses among the PTD subjects (Kubitz, 2013) . A recent systematic review of the global prevalence of common mental disorders (Baxter, 2014) found age-standardized MDD prevalences in East Asia (3.8% of females, 2.3% of males) and in Asia Pacific (3.2% of females, 1.9% of males) substantially below the worldwide prevalence (5.5% of females, 3.3% of males). The reasons for this variability are unclear, but Chien in a study of Taiwan's health care data from 1996 through 2003 (Chien, 2007) estimated the annual incidence of MDD as approximately 2/1000 person-years, concluded that MDD was underdiagnosed and undertreated in Taiwan, and suggested as possible explanations the greater availability of consistent social support, low rate of broken families, low comorbidity rates, and the possibility that depression may manifest differently in Chinese culture, e.g., as neurasthenia or somatization. To our knowledge there have been few, if any, population-based studies of TRD in Asia-Pacific populations. Thus, there is a need for more information on the epidemiology of TRD for public health purposes, and to inform the effort to develop better treatments.
The concept of TRD involves depression that fails to improve adequately with treatment with antidepressant (AD) medications at doses and durations that would normally be effective, administered to a patient believed to be adherent (European Medicines Agency, 2013) . However, definitions differ regarding what treatments should be considered in counting failed treatments: AD medications only (European Medicines Agency, 2013), a wider class of medications including antipsychotics (Corey-Lisle, 2002; Kubitz, 2013) , or a still wider range including hospitalization or electroconvulsive therapy (ECT) (Gibson, 2010) . There are also differences regarding the number of failures required to define a patient as having TRD (Berlim and Turecki, 2007; Fava, 2003; Harald and Gordon, 2012) , and whether the failed AD medications must come from different classes (Berlim and Turecki, 2007; European Medicines Agency, 2013; Ruhe, 2012) . Two failures of AD medications, not necessarily from different classes is a standard supported by the data (Ruhe, 2012; Rush, 2006) . It is widely used (European Medicines Agency, 2013; Kubitz, 2013) , recognized by regulators (European Medicines Agency, 2013) and is the standard adopted in the present study. Because TRD is defined in terms of AD medication failures, TRD can only develop in depression that is pharmaceutically treated. Guidelines for clinical trials (European Medicines Agency, 2013) and clinical trial protocols typically define TRD as a subset of MDD, and protocols typically set strict standards for the diagnosis of MDD. However, in clinical care, diagnostic labels may not be applied with this level of precision, and observational studies from health care databases have based their definition of TRD on PTD that comprised not only MDD, but also other types of depression including dysthymic disorder (Kubitz, 2013) and adjustment reaction with depressed mood (Gibson, 2010) .
Studies of TRD typically interpret failure of an AD medication as failure during a clinical episode of depression (Fava, 2003; Fekadu, 2009; Harald and Gordon, 2012; McIntyre, 2014; Mrazek, 2014; Nemeroff, 2007; Zhou, 2014) , and trials of medications for TRD typically enroll patients who are currently depressed although treated with one or more AD medications, i.e. such trials are focused on treatment resistance within a single clinical episode, and are conducted for a limited period of time. Thus, though it's not always explicit, the definition of TRD focuses on failure to relieve depression during a clinical episode.
Household surveys (Bromet, 2011; Pratt, 2014) and data from groups of care providers (Gaynes, 2007; Yates, 2004) provide substantial information on the epidemiology of depression. Retrospective tabulations from health care databases use different criteria for depression and report rates that typically differ from the household surveys, but have also been rich sources of information on the epidemiology, treatment, and costs of depression (Andrade, 2003; Chien, 2007; Fu, 2006; Onishi, 2013) and of TRD (Corey-Lisle, 2002; Crown, 2002; Greenberg, 2004; Ivanova, 2010; Kubitz, 2013; Olchanski, 2013) . Such studies have typically used changes of AD medication regimens (augmentation, dose titration, switching, or addition of a new medication) as evidence of a regimen's failure (Gibson, 2012; Greenberg, 2004; Harald and Gordon, 2012) .
Because people who have had an episode of depression are at increased risk, psychiatrists may treat depressed patients prophylactically between episodes of clinical depression (Bondolfi, 2010; Kumar, 2003; Spanier, 1996) . American Psychiatric Association (APA) practice guidelines for MDD recommend that patients who have been treated successfully with AD medications in the acute phase should continue treatment with the same medication and dosage for 4-9 months, and may require some form of maintenance therapy indefinitely (American Psychiatric Association, 2010). Though one retrospective database study used a period free of AD medication dispensings and outpatient depression diagnoses (Kubitz, 2013) as evidence that an episode has ended, most retrospective database studies cited above either followed the subjects to the end of the available data or for a fixed time period of up to 2 years. Except for a single retrospective database study that limited observation to a short fixed time period after the first AD medication was given, i.e., to a period when the subject was likely to be clinically depressed (Byford, 2011) , none of the retrospective database studies cited above distinguished between the use of AD treatment for ongoing clinical depression versus prophylactic treatment after the clinical episode had ended (Corey-Lisle, 2002; Crown, 2002; Gibson, 2010; Russell, 2004) . To the extent that this led to over-counting medication failures, these studies may have overestimated the proportion of episodes that became TRD.
Methods
The data for this study came from a random sample of approximately 1 million participants in Taiwan's National Health Insurance program (NHIRD) for 2005, a large population-based claims database provided by the Taiwan National Health Research Institute. The claims are from the National Health Insurance program, implemented in March 1995 and providing mandatory universal health insurance for approximately 99% of the more than 23 million people residing in Taiwan. The NHIRD offers a comprehensive set of patient and clinical information on demographics, ICD-9 diagnostic codes, procedures, dispensed prescription drugs, and expenditures. All personally identifiable information is encrypted to protect patient privacy. The NHIRD has provided the data for many recently published peer-reviewed studies Wu, 2016; Yang, 2017; Yin, 2016) . In the present study, AD medication dispensings with missing values for days' supply were assigned 30 as the days' supply. Analyses were done in SAS version 9.4 and Episheet (Rothman, Accessed April 20, 2016) . Comparisons of incidence by sex or by age group were assessed for statistical significance based on a chi-square statistic applied to the number of subjects in each group.
Patients were eligible for inclusion in the PTD cohort if they were aged >= 18 in 2005, enrolled in the database continuously since January 1, 2004 (ignoring breaks of < 30 days), and, in the last 4 months of 2004, had not received an exclusion diagnosis, a diagnosis of depression, or a dispensing of an AD medication. These last conditions were imposed to assure the depression episodes were of new onset rather than ongoing, i.e., were incident rather than prevalent. The exclusion diagnoses and their respective ICD-9 codes were mania or bipolar disorder (296), schizophrenia (295), and dementia (290, 294) . MDD with psychotic behavior was not an exclusion diagnosis. Subjects were included in the cohort at the onset of their first episode of PTD, i.e., when they were dispensed an AD medication within 30 days either before or after a diagnosis of depression. A diagnosis of depression was defined by an ICD-9 code of: 296.2 (MDD single episode), 296.3 (MDD recurrent episode), 300.4 (dysthymic disorder, depressive) or 311 (depressive disorder NOC). The subject's index date for PTD was the date of that dispensing, and was required to fall in 2005. An episode ended when the subject had 120 days with no diagnosis of depression and no dispensing of an AD medication. Follow-up ended with the first of: Meeting an exclusion criterion, the end of the last episode that began in 2005, the end of the study period (December 31, 2013) . No subject was allowed to enter the cohort more than once.
A regimen failed if, at least 15 days after it began, a regimen of a different AD medication was begun. The change could be a substitution or addition and need not be from a different class. The failure date of the earlier regimen was the date when the later regimen began, but the end date of the earlier regimen was not affected, i.e., the two regimens could overlap. An episode of PTD became an episode of TRD on the date (the TRD index date) when the second AD medication regimen failed but the episode also remained an episode of PTD with its original index date. AD medication regimens were required to have ≥42 days' supply, and at least one dispensing whose daily dose was greater than or equal to the minimum effective daily dose described in the Massachusetts General Hospital's questionnaire (Desseilles, 2011) or (for medications not so classified) the World Health Organization's Defined Daily Dose. A regimen began with the first dispensing of the medication, and ended when the end of the days' supply plus 30 days had passed without a dispensing. Though the PTD index date was required to fall in 2005, the TRD index date was not required to fall in 2005. A subject who had an episode of PTD was classified as a PTD case. One who had an episode of TRD was also classified as a TRD case. PTD cases who did not meet the criteria for TRD before the end of follow-up were classified as having unknown TRD status. Such cases were not included in the estimates of TRD incidence.
The initial descriptive tables, reflecting a median time from onset of PTD to onset of TRD of more than a year, were reviewed with the study's local psychiatrists (FY, MW) who stated that if a depressed patient did not have a satisfactory response to an AD medication, the patient would be changed to a different AD medication in 6 to 12 weeks. This was confirmed by conversations with several other independent psychiatrists working in Taiwan, and was consistent with several guidelines that suggest changing treatment after 3 to 16 weeks, depending on the response observed (American Psychiatric Association, 2010; National Institute for Health and Clinical Excellence (NICE), 2010). In Taiwan, patients with depression typically receive treatment from psychiatric specialists, so this process of searching for an effective AD medication could be expected to begin promptly. Thus, a depressed patient who was not getting adequate relief should reach the third AD medication (and thus have two failed AD medication regimens and meet the criterion for TRD) in no more than 3 months for each of the two failed regimens, i.e. in no more than 6 months. This suggested that some of the AD medication changes we counted in determining whether a patient had TRD were not occurring during episodes of clinical depression but were instead occurring during prophylactic treatment between episodes. Such AD medication changes were unlikely to reflect inadequate relief of depression because these patients were not clinically depressed at the time of the change of AD therapy. The changes may have been driven by other considerations, e.g., by convenience, or by bradyphylaxis (later failure of an initially successful AD medication after a period of success), and thus should not have been counted as failures to produce adequate improvement. To address this concern, we developed a second set of tabulations that were the same as the first set except that a subject was classified as having TRD only if the time from the PTD index date to the TRD index date was six months or less. Subjects with PTD who did not meet this criterion were classified as having PTD but not TRD. Results of these tabulations are shown as a supplement.
We estimated the prevalence of PTD and TRD as incidence times duration, and did not address the aging of the study population, i.e., we assumed a stable distribution. In view of the uncertainties about the meaning of prevalent PTD or TRD (the extent to which it represents time during episodes of depression vs. time during prophylaxis between episodes of depression), we did not offer confidence intervals for the prevalence estimates.
Results
Of the 704,265 subjects in the database in 2005 who were aged ≥ 18 years, 17,864 had a diagnosis of depression and 2,751 met the criteria for incident PTD (Figure 1 ). The main reasons for not meeting the criteria for incident PTD were 1) Having a diagnosis of depression or a dispensing of an AD medication in the last 4 months of 2004, and 2) Not having both a diagnosis of depression and a dispensing of an AD medication within 30 days of each other during 2005. In the main analysis with no cap on the time from the PTD index date to the TRD index date, 576 subjects (20.94%, 95% CI (19.46, 22.49)) developed TRD (Table 1) .
Among the subjects with PTD, 997 (36.24%) were male, and 200 (20.06%) of these developed TRD; 1,754 (63.76%) were female and 376, (21.44%) of these developed TRD (Table 1 ). In the supplemental posthoc analysis with a 6-months cap on the time from the PTD index date to the TRD index date, the number of subjects with PTD was the same, but only 68 (2.47%) of these subjects met the criteria for TRD (Supplemental Table 1 ). Among the 21 male PTD subjects, (2.11%) developed TRD, and among the 47 female PTD subjects, (2.68%) developed TRD (Supplemental Table 1 ). The proportion of people with PTD who developed TRD did not differ significantly by sex in either analysis (p = 0.39, p = 0.35, respectively).
In both the main analysis and the supplemental analysis, the mean Charlson Comorbidity Index was 0.5 (standard deviation [SD] 0.9) for subjects with PTD who did not develop TRD, and 0.6 (SD 0.9) for subjects who developed TRD. The comorbidities diagnosed among more than 1% of the subjects with PTD were: Peptic ulcer disease (11.5%), chronic pulmonary disease (7.7%), diabetes (6.6%), mild liver disease (5.8%), cerebrovascular disease (4.5%), malignancy (2.9%), renal disease (2.3%), diabetes with chronic complications (1.7%), and congestive heart failure (1.4%).
In both analyses, the incidence of PTD in 2005 was 3.91/1,000 population, 95% CI (3.76, 4.05), approximately twice the incidence of MDD observed in the earlier study from Taiwan (Chien, 2007) . In the main analysis, the incidence of TRD in 2005 was 0.82/1,000 population, 95% CI (0.75, 0.89), the incidence of PTD and TRD were higher among females than among males in each age group, P < 0.001 except for TRD in 18-29 year olds where the incidences were not significantly different by sex. Within each sex group, the incidence of PTD and TRD increased with age, P < 0.001 -though TRD incidence among females aged >= 60 was slightly lower than among females aged 50-59 (Table 1 ). In the supplemental analysis, the incidence of TRD in 2005 was 0.10/1,000 population, 95% CI (0.08, 0.12). There were too few subjects in each age and sex group to apply similar statistical testing for TRD incidence differences by sex or age group (Supplemental Table 1 ). The incidence and prevalence estimates for all subjects were approximately 8-fold and 15-fold higher, respectively, in the main analysis than in the supplemental analysis. Of note, these are the estimated prevalences at a point in time, not the lifetime cumulative incidences of these conditions. Of the subjects with PTD, 49 had a second episode that started in 2005, and none had a third such episode. In the main analysis 10 of these second episodes developed into TRD. None of the 49 second episodes met the criteria for TRD in the supplemental analysis.
In the main analysis, the median time from onset of PTD to onset of TRD was 416 days (25 th percentile 266 days, 75 th percentile 721 days). In the supplemental analysis, it was 148 days (25 th percentile 121 days, 75 th percentile 166 days).
Consistent with reports from other countries, SSRI's were the AD medication class most often used. They represented more than half of first regimens and, though they tended to be replaced by other classes of AD medications in later regimens, they were the class most often used even in the later regimens. As in other countries, antipsychotics were commonly added to AD medication regimens. More than a quarter of PTD cases that did not develop TRD, more than a third of TRD cases, and more than half of PTD cases whose TRD status was unknown were treated with antipsychotics in addition to AD medications. Sulpiride was the antipsychotic most often used, followed by prochlorperazine, quetiapine, risperidone, and haloperidol. The proportion of subjects who received antipsychotic medications increased with the number of treatments. Electroconvulsive therapy was rarely used and each of the 4 subjects who received it had had at least three prior AD medication regimens. The predominance of SSRI's and the frequent use of antipsychotic medications in addition to AD medications, were seen in both the main analysis and the supplemental analysis (Table 2 and  Supplemental Table 2 ).
The numbers of subjects with PTD according to their depression diagnoses at cohort entry and the proportion developing TRD are shown in Table 3 . Among the 805 subjects with PTD who entered the study cohort with an MDD diagnosis, 184 (22.86%) developed TRD. Among the 1,946 who entered the study cohort with another type of depression diagnosis (dysthymic disorders (depressive) or depressive disorder not elsewhere classified), 392 (20.14%) developed TRD (p = 0.11). In the supplemental analysis 31 (3.85%) of the 805 subjects who entered the study cohort with an MDD diagnosis, and 37 (1.90%) of those who entered the study cohort with a different depression diagnosis developed TRD (p = 0.003) (Supplemental Table 3 ). In both analyses, the majority of the subjects with TRD entered the study with depression diagnoses other than MDD.
Discussion
This study is the first to offer estimates for the incidence and prevalence of TRD and PTD in an Asia/Pacific population. Its estimates for TRD are also unusual in that they are not calculated simply as a proportion of subjects with PTD, but also as a proportion of the adult population of the country. The study includes a main analysis and supplemental analysis. The latter was necessary because in the main analysis the long time from onset of PTD, as marked by the first dispensing of an AD medication, to the start of TRD, as marked by the start of the third AD regimen was substantially longer than would be consistent with clinical practice, in which AD medications would be changed within 3 months if they were not adequately effective, so two such changes should take <= 6 months. This analysis is termed supplemental because it had not been envisioned in the original protocol. The main analysis' estimate that 21% of PTD cases become TRD cases is approximately at the mid-point of the estimates of 6.6% to 35% from recent population-based studies (Kubitz, 2013; Nemeroff, 2007; Rush, 2006) . The results of the main and supplemental analyses are consistent with previous studies in finding that both MDD and TRD are more common among females than among males (Bromet, 2011; Chien, 2007; Conway, 2015; Corey-Lisle, 2002) , and that SSRI's are the mainstay of treatment for PTD (Kubitz, 2013) , especially initially.
A previous retrospective study (Kubitz, 2013) identified a median time of more than a year from onset of PTD to onset of TRD, but few (Byford, 2011) have addressed the fact that this is substantially longer than is consistent with the strategies for changing AD medications recommended by the APA and NICE, and reported by Taiwan psychiatrists. We have argued that, in studies that do not address this point, many of the episodes classified as TRD may represent, not a single clinical episode in which two AD medications have failed, but two or more clinical episodes linked by periods of prophylaxis, with the second failure occurring after the end of the first clinical episode, i.e. during prophylaxis or during a second clinical episode. Thus, such studies would over-estimate the incidence of TRD. Without the 6-month limitation on the time from onset of PTD to onset of TRD, the present study's estimate of the proportion of PTD that becomes TRD is consistent with estimates from previous retrospective database studies. With the 6-month limitation it is substantially lower. Thus, the question of how to define the end of an episode of PTD, i.e., how to differentiate between the clinical episode and prophylaxis, emerges as a key methodological issue for retrospective studies of TRD from health services databases.
A second important methodological point emerging from the present study concerns the depression diagnoses (MDD only, or some wider selection of depression diagnoses) that should be used to identify TRD cases. In the main analysis, the proportion of PTD subjects who developed TRD was similar for those who entered the cohort with MDD and for those who entered with other depression diagnoses, but, because the latter group was larger, it accounted for the majority of TRD cases. In the supplemental analysis, the proportion of subjects who developed TRD was higher among those who entered the cohort with a diagnosis of MDD than among those who entered with other depression diagnoses but again the latter group accounted for the majority of the TRD cases. Thus, studies limited to MDD may miss substantial numbers of subjects who have TRD in the sense that their depression fails to respond to 2 or more AD medication regimens.
The estimates of the prevalence of PTD and TRD reflect the study's definition of the duration of an episode of depression, i.e., an episode of depression ends when 120 days pass with no diagnosis of depression and no dispensing of an AD medication. As discussed above, many episodes of depression defined in this way include not only periods of clinical depression, but also periods of prophylaxis between them. Thus, this study's estimates of the prevalence of PTD and TRD, respectively, should be interpreted as the prevalence of treatment, including prophylactic treatment for these conditions, rather than the prevalence of clinical depression with these conditions.
Rather than focus on cases whose depression began more recently, we chose to study cases whose PTD began in 2005 and follow them through 2013 so we would have ample follow-up time to identify subjects who developed TRD, estimate the time from onset of PTD to onset of TRD, and estimate the durations of the depression episodes. This allowed us to recognize and address the implausibly long time from onset of PTD to TRD, an issue that prior database studies had not explicitly addressed. However, it also raises the question of how much the epidemiology of TRD and PTD have changed since 2005. There are insufficient data to assess this directly for TRD (Kubitz, 2014) but between 1990 and 2010, the global prevalence of MDD has not changed (Baxter, 2014) and, though we could not identify relevant studies for Taiwan, the prevalence of MDD in China has not changed between 1990 and 2013 (Baxter, 2016) . Thus, it appears that the prevalence of MDD has not changed substantially since 2005. Among the strengths of this study are that it was based on a protocol registered in advance with ClinicalTrials.gov; described the population incidence and prevalence of PTD and TRD in an Asia-Pacific population where no similar work on TRD has been reported; was based on data from a representative national database; and provided population-based incidence and prevalence estimates in addition to estimates of the proportion of PTD that became TRD. It required that for an AD regimen to fail it must have adequate dose and duration, and the duration requirement of 42 days' supply exceeded the usual 30 days' supply of a single dispensing so the AD medication regimens typically included a second dispensing, suggesting some adherence to the regimen Among the limitations of this study were the adoption of three analytic strategies that differed from those in the protocol: 1) A simplification of the definition of adequate dose of AD medication (from an average daily dose at or above the minimum effective dose for some 42 day window to at least one dispensing with a daily dose at or above the minimum effective dose); 2) A change in the definition of the PTD index date (from the date of diagnosis of depression or the date of dispensing of the first AD medication, whichever came first to the date of dispensing of the first AD medication); and 3) A change from tabulating all episodes of PTD that began in 2005 to tabulating only the first such episode. Because the definition of PTD limited the time between the dispensing of an AD medication and diagnosis of depression to 30 days, and because, as shown above, the exclusion of PTD episodes in 2005 after the first excluded only a small proportion of TRD cases, neither of these last two changes was likely to have substantially affected the study's findings.
Another important limitation was that antipsychotic medications were frequently used to supplement AD medications but this study defined the failure of a regimen in terms of AD medications only. To the extent that supplementation with antipsychotic medications delayed the time to change a patient who was not getting adequate relief from the current AD medication to a new AD medication, the analysis with the 6-month cap on the time from onset of PTD to onset of TRD may have used too strict a time limitation and thus underestimated the incidence of TRD. To the extent that such supplementation was evidence of failure of an AD medication, it may have led to underestimation of the incidence of TRD in both the main analysis and the supplemental analysis. Other possible causes of underestimation of the incidence of TRD include under-diagnosis of depression in Taiwan (Chien, 2007) , and the possibility of a depressed subject withdrawing from treatment after a first AD medication that did not provide relief. Finally, replacement of medication regimens for reasons other than unsatisfactory response would lead to overestimation of the incidence of TRD.
In contrast to many other countries, the national reimbursement policies of Taiwan discourage the concurrent dispensing of multiple AD medications. It is uncertain how this policy affected the above observations or affected the use of antipsychotics as augmentation.
The proportion of PTD cases that developed TRD in the supplemental analysis is substantially lower than the proportion of MDD cases that developed TRD in clinical trials, e.g., STAR*D (Rush, 2006) . This difference may reflect the fact that participants in clinical trials are not usually representative of the population, and the fact that the present study was not limited to subjects with MDD, but also included subjects with dysthymic disorder, and depressive disorder NOC.
As usual in retrospective studies from health services databases, we knew what medications were dispensed, not what medications were taken. This study also did not capture non-pharmaceutical treatments, e.g., psychotherapy.
Conclusion
We used a random sample of 704,265 subjects aged > 18 years from Taiwan's National Health Insurance Research database (NHIRD) to describe the epidemiology of TRD in Taiwan. In doing this, we identified TRD based on failure of two antidepressant (AD) medication regimens. Our approach differed from prior studies in several potentially important ways: 1) We required the AD medication regimens to have adequate dose. 2) We limited the study subjects to those who developed a new depression episode in a single year, 2005, so few subjects had more than one episode of depression during the study. This allowed us to set up a cohort of new-onset depression cases and track them until their depression resolved, they developed TRD, or their follow-up ended with their TRD status undetermined. 3) We followed the subjects for approximately 8 years so we could estimate the duration of their depression episode. 4) We provided an alternative analysis to take account of the fact that, for many subjects, the long time from onset of depression to onset of TRD suggested that some of their changes of AD medications were taking place during prophylaxis between clinical depression episodes rather than during a single clinical episode. The substantial difference between the findings of the main analysis and the latter analysis suggests this is a methodological issue that needs further research for database studies of TRD. In addition to describing the epidemiology of TRD in Taiwan and thus helping to fill the gap in information about TRD in the Asia Pacific region, this work sought to build on, and strengthen, the methods used in earlier studies of TRD from health insurance databases. Antipsychotic medication were used concurrently by 36% to 45% of the TRD cases, 51% to 58% of the PTD cases with TRD status unknown, and 26% to 29% of the PTD cases who did not develop TRD. Each row excludes the diagnoses already captured in the rows above so no subject is captured in more than one row.
Highlights
 Treatment resistant depression (TRD) was defined by 2 failed antidepressant regimens  TRD developed in 21% of depressed subjects  The median time from depression onset to TRD onset was 14 months  Ineffective antidepressant regimens would normally be changed within 3 months  Only 2.5% of depressed patients develop met the criteria for TRD within 6 months
